

To,
The Manager,
Listing Department
National Stock Exchange of India Ltd
'Exchange Plaza'
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir/Madam,

Sub: Updates - Alembic Pharmaceuticals Limited announces launch of desvenlafaxine succinate extended release tablets by its partner

This is to inform the exchange that the Company announces launch of desvenlafaxine succinate extended release tablets, 50mg and 100 mg by its partner Breckenridge Pharmaceutical, Inc.

Please find enclosed herewith our press release.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited



R. K. Baheti
Director – Finance & CFO

Encl.: A/a.

PRESS RELEASE

3rd March, 2017, Vadodara, India

Alembic Pharmaceuticals announces launch of desvenlafaxine succinate extended release tablets by its partner

Alembic Pharmaceuticals Ltd today announced the launch of desvenlafaxine succinate extended-release tablets 50mg and 100mg by its partner Breckenridge Pharmaceutical, Inc. In Jun'15, Alembic had received final approval of its ANDA which is therapeutically equivalent to the reference listed drug Pristiq® of Pfizer Inc. The ANDA was filed as a Paragraph IV on the first-to-file date and will share 180-day exclusivity with other ANDA first filers. Alembic Pharmaceuticals Limited is the manufacturer of the ANDA, which will be marketed exclusively by Breckenridge. The Paragraph IV litigation was settled on terms that are confidential.

Desvenlafaxine is a prescription drug that is indicated for the treatment of major depressive disorder, and is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SNRIs). Pristiq® had an estimated sales of \$883 million for twelve months ending December, 2016 according to IMS.

Alembic has a total of 52 ANDA approvals (46 Final approvals and 6 tentative approvals) from USFDA.

About Alembic Pharmaceuticals Limited:

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients. Information about the company can be found at <http://www.alembicpharmaceuticals.com>; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

About Breckenridge:

Breckenridge Pharmaceutical, Inc. is a privately-held own-label distributor that performs pharmaceutical marketing, research and development, as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: tablets, capsules, soft gel capsules, liquids, suspensions, ophthalmics, nasal sprays and powders. www.bpirx.com

For more information contact:

Ajay Kumar Desai Phone: +91 22 - 306 11681 Email: ajay.desai@alembic.co.in	Mitanshu Shah Phone: +91 265 - 3007630 Email: mitanshu.shah@alembic.co.in
--	--



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-0265-2280550 • FAX : +91-0265-2282837
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

CIN: L24230GJ2010PLC061123